title: Upregulation of orphan nuclear receptor Nur77 following PGF(2alpha), Bimatoprost, and Butaprost treatments. Essential role of a protein kinase C pathway involved in EP(2) receptor activated Nur77 gene transcription.
abstract: 1. Using gene chip technology, we first identified that PGF(2alpha) (FP agonist) and Butaprost (EP(2) agonist) induced about a five-fold upregulation of Nur77 mRNA expression in hFP-HEK 293/EBNA and hEP(2)-HEK293/EBNA cells. Northern Blot analysis revealed that PGF(2alpha)- and Butaprost-induced upregulation of Nur77 expression are dose- and time-dependent. 2. Both PGF(2alpha) and Butaprost upregulated Nur77 gene expression through the protein kinase C (PKC) pathway. These data are the first showing a link between EP(2) receptor stimulation and protein kinase C activation. Calcineurin was found to be involved downstream of the PKC pathway in PGF(2alpha)-induced Nur77 expression, but not in Butaprost-induced Nur77 expression. 3. We also used Nur77 as a marker gene to compare the effects of PGF(2alpha), Butaprost, and Bimatoprost (a prostamide) on Nur77 expression in human primary trabecular meshwork and ciliary smooth muscle (SM) cells, which are target cells for antiglaucoma drugs. The results showed that PGF(2alpha) and Butaprost, but not Bimatoprost, induced upregulation of Nur77 expression in human TM cells. PGF(2alpha), but not Bimatoprost, dramatically induced upregulation of Nur77 mRNA expression in human ciliary SM cells, whereas Butaprost slightly upregulated Nur77 mRNA expression in SM cells. 4. Nur77 promoter deletion analysis indicated that PGF(2alpha), but not Bimatoprost, activated Nur77 promoter-luciferase reporter in hFP-HEK 293/EBNA cells. Butaprost was less efficacious in inducing Nur77 promoter-luciferase reporter activity in hEP(2)-HEK293/EBNA cells relative to PGF(2alpha) in the comparable assay. The data for Nur77 promoter functional analysis were matched to the Northern blot analysis. 5. It appears that PGF(2alpha) and Butaprost activate Nur77 transcription mechanisms through the activation of FP and EP(2) receptor-coupled signaling pathways, whereas Bimatoprost stimulates neither FP nor EP(2) receptors.
authors.affiliation: Department of Biological Science, Allergan, Inc, Irvine, CA 92612, USA. Liang_Yanbin@allergan.com
authors.forename: Yanbin
authors.initials: Y
authors.lastname: Liang
authors.forename: Chen
authors.initials: C
authors.lastname: Li
authors.forename: Victor M
authors.initials: VM
authors.lastname: Guzman
authors.forename: William W
authors.initials: WW
authors.lastname: Chang
authors.forename: Albert J
authors.initials: AJ
authors.lastname: Evinger
authors.forename: Jozelyn V
authors.initials: JV
authors.lastname: Pablo
authors.forename: David F
authors.initials: DF
authors.lastname: Woodward
mesh_terms: D000527:Alprostadil / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D000577:Amides; D000069580:Bimatoprost; D002460:Cell Line; D002924:Ciliary Body / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D003008:Cloprostenol / Q000031:analogs & derivatives; D004268:DNA-Binding Proteins / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D015237:Dinoprost / Q000494:pharmacology* / Q000627:therapeutic use; D019309:Epstein-Barr Virus Nuclear Antigens / Q000737:chemistry; D006801:Humans; D015151:Immunoblotting / Q000379:methods; D007700:Kinetics; D008055:Lipids / Q000494:pharmacology* / Q000627:therapeutic use; D008156:Luciferases / Q000235:genetics; D057105:Nuclear Receptor Subfamily 4, Group A, Member 1; D011401:Promoter Regions, Genetic / Q000502:physiology; D011493:Protein Kinase C / Q000502:physiology*; D012313:RNA / Q000235:genetics / Q000302:isolation & purification; D018160:Receptors, Cytoplasmic and Nuclear; D018078:Receptors, Prostaglandin E / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D058307:Receptors, Prostaglandin E, EP2 Subtype; D011987:Receptors, Steroid; D014129:Trabecular Meshwork / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D014157:Transcription Factors / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D014158:Transcription, Genetic / Q000502:physiology; D014162:Transfection / Q000379:methods; D015854:Up-Regulation / Q000235:genetics
chemical_list: D000577:Amides; D004268:DNA-Binding Proteins; D019309:Epstein-Barr Virus Nuclear Antigens; D008055:Lipids; C539821:NR4A1 protein, human; D057105:Nuclear Receptor Subfamily 4, Group A, Member 1; C545644:PTGER2 protein, human; D018160:Receptors, Cytoplasmic and Nuclear; D018078:Receptors, Prostaglandin E; D058307:Receptors, Prostaglandin E, EP2 Subtype; D011987:Receptors, Steroid; D014157:Transcription Factors; D003008:Cloprostenol; D012313:RNA; D015237:Dinoprost; D008156:Luciferases; D011493:Protein Kinase C; D000527:Alprostadil; C048491:butaprost; D000069580:Bimatoprost